PBI16 Betibeglogene Autotemcel GENE Therapy (BETI-CEL) Is Cost-Effective Versus Standard of Care in Patients with Transfusion-Dependent B-Thalassemia (TDT) in France
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.094
https://www.valueinhealthjournal.com/article/S1098-3015(20)32350-0/fulltext
Title :
PBI16 Betibeglogene Autotemcel GENE Therapy (BETI-CEL) Is Cost-Effective Versus Standard of Care in Patients with Transfusion-Dependent B-Thalassemia (TDT) in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32350-0&doi=10.1016/j.jval.2020.08.094
First page :
Section Title :
Open access? :
No
Section Order :
10069